Hostname: page-component-cb9f654ff-lqqdg Total loading time: 0 Render date: 2025-09-02T06:56:44.120Z Has data issue: false hasContentIssue false
  • English
  • Français

Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections

Published online by Cambridge University Press:  21 February 2018

Rupal M. Patel ,
Larry K. Kociolek ,
Emily Merrick ,
Caroline Reuter ,
Kenny Kronforst ,
Xiaotian Zheng  and
Sameer J. Patel
Rupal M. Patel*
Affiliation:
Pediatric Antimicrobial Support Network, Carolinas Healthcare System, Charlotte, North Carolina
Larry K. Kociolek
Affiliation:
Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Emily Merrick
Affiliation:
Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
Caroline Reuter
Affiliation:
Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
Kenny Kronforst
Affiliation:
Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois Division of Neonatology, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
Xiaotian Zheng
Affiliation:
Department of Pathology and Laboratory Medicine, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IIllinois.
Sameer J. Patel
Affiliation:
Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois
*
Address correspondence to Rupal Patel, PharmD, 1000 Blythe Blvd, Charlotte, NC, 28203 (rupal.patel@carolinashealthcare.org).
Get access Rights & Permissions [Opens in a new window]

Abstract

Transitioning from administration of monthly palivizumab to a single dose at discharge was associated with substantial pharmacy cost savings. With the concurrent adoption of private hospital rooms and visitor restriction policies, hospital-wide and neonatal intensive care unit healthcare-associated respiratory syncytial virus infections decreased following these changes.

Infect Control Hosp Epidemiol 2018;39:485–487

Information

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 4 , April 2018 , pp. 485 - 487
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1. Jain, S, Williams, DJ, Arnold, SR, et al. Community-acquired pneumonia requiring hospitalization among US children. N Engl J Med 2015;372:835–845.Google Scholar
2. Stockman, LJ, Curns, AT, Anderson, LJ, Fischer-Langley, G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012;31:5–9.Google Scholar
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531–537.Google Scholar
4. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442–1446.Google Scholar
5. Vendetti, N, Gerber, JS, Sammons, JS, Fisher, BT, Zaoutis, TE, Coffin, SE. Administration of palivizumab in the NICU. Hosp Pediatr 2016;6:354–358.Google Scholar
6. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694–1701.Google Scholar
7. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:415–420.CrossRefGoogle Scholar
8. Zembles, TN, Gaertner, KM, Gutzeit, MF, Willoughby, RE. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital. Am J Health Syst Pharm 2016;73:405–408.CrossRefGoogle Scholar
9. Ohler, KH, Pham, JT. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus. Am J Health Syst Pharm 2013;70:1342–1346.Google Scholar